Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Esperion Therapeutics (ESPR) Looks Good: Stock Gains 10.4%
Esperion Therapeutics, Inc. (ESPR - Free Report) was a big mover last session, as the company saw its shares jump a little above 10% on the day. The move came after a regulatory pathway for its cholesterol-lowering combination was approved by the Food and Drug Administration. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 53% in the past one-month time frame.
The company has seen no positive or negative estimate revision in the past 30 days. But its Zacks Consensus Estimate moved lower over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Esperion Therapeutics currently carries a Zacks Rank #3 (Hold).
Esperion Therapeutics, Inc. Price
Esperion Therapeutics, Inc. Price | Esperion Therapeutics, Inc. Quote
A better-ranked stock in the Medical - Drugs industry is Aerie Pharmaceuticals, Inc. holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is ESPR going up? Or down? Predict to see what others think: Up or Down
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>